The approvals of Onpattro, Givlaari, Oxlumo, and Leqvio combined with several partnerships have bolstered Alnylam's cash balance, and the company concluded fiscal 2024 with $2.69 billion in cash, cash ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.46% to $590.00 Thursday, on what proved to be an all-around positive ...

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we ...

MML Investors Services ramped up its Regeneron stake by 41.7%, acquiring 2,218 additional shares during Q4. This brings their ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around ...

Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

The FDA does not plan a reorganization of the agency but will consolidate offices that handle travel and IT ...

President Trump’s proposed 25% tariff on pharmaceutical imports, largely from Ireland, could raise U.S. drug costs by nearly ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...